MET基因突变包括第14外显子跳读和基因扩增等,会导致MET通路的异常激活,从而驱动癌细胞的增殖、迁移,促进肿瘤发展。回顾性研究显示,中国PSC患者中MET14外显子跳变的发生率为20.8%-22%。 2018年,Li等在77名PSC患者的研究中显示,对比驱动基因阴性...
9510-Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆). 9519-Phase II study of savolitinib in patien...
Methods also are provided for detecting the presence of the Met (Ex14del) mutant protein.Tian YuanCecchi FabiolaHembrough Todd
It turns out that this exon 14 skipping, the juxtamembrane domain deletion, is an important biomarker to select out the patients for certain drugs that they respond to. What is the future of MET as a drug target? At the same time, MET amplification seems to be also pretty good....
1.Abstract9510: Safety and preliminary clinical activity of the MET antibody mixture,Sym015 in advanced non-small cell lung cancer (NSCLC) patients with METamplification/exon 14 deletion (METAmp/Ex14Δ). 2.Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer...
2 Almost all of the MET exon 14 mutations described to date cause skipping of MET exon 14 during pre-mRNA splicing, generating an in-frame, 47–amino acid deletion of the MET juxta-membrane domain with loss of the Y1003 c-Cbl binding site.3 Several studies have proven that all of the...
[9] Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med 2020;26:47-51. [10] Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Re...
1.Abstract9510: Safety and preliminary clinical activity of the MET antibody mixture,Sym015 in advanced non-small cell lung cancer (NSCLC) patients with METamplification/exon 14 deletion (MET Amp/Ex14Δ). 2.Capmatinib in patients with high-level MET-amplified advanced non–small cell lung ...
Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14Δ) NCT02648724是一项正在进行的I/II期临床研究旨在评估Sym01...
图5. markSV算法从220例既往检测驱动基因全阴样本当中检出2例MET-ex14跳读突变,两例均是较长的deletion突变(141bp和79bp) 综上所述,除RNA测序外,DNA测序同样能够实现高灵敏度和特异性检测MET-ex14跳读,但有三点非常重要:(1)文库构建方法:探针捕...